As you might know, Haemonetics Corporation ( NYSE:HAE ) just kicked off its latest quarterly results with some very strong numbers. The company beat both earnings and revenue forecasts, with revenue of US$240m, some 7.2% above estimates, and statutory earnings per share (EPS) coming in at US$0.62, 58% ahead of expectations. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.